Roche Glycart Companies
Roche Glycart develops antibody drug candidates, which include GA101, a humanized anti-CD20 monoclonal antibody to increase direct- and immune-mediated target cell death
Investors
Founded Date:
2000
Industry:
P4 Medicine
Headquarters:
Schlieren, Zurich, Switzerland